From: Cost-utility of tiotropium in patients with severe asthma
Variable | Inputs used in the sensitivity analysis | References | ||
---|---|---|---|---|
Base case | Upper range | Lower range | ||
Cost tiotropium (per 4 week cycle) (U$) | 71 | 89 | 53 | |
Annual cost of health state asthma controlled (U$) | 38 | 47 | 28 | [19] |
Annual cost of health state OCS burst (per episode) (U$) | 38 | 47 | 28 | |
Annual cost of health state ED visit (per episode) (U$) | 2648 | 3310 | 1986 | |
Annual cost of health state hospitalization (per episode) (U$) | 230 | 288 | 173 | |
Utilities (annual) | ||||
Utility of controlled state | 0.740 | 0.93 | 0.56 | [13] |
Utility decrement | ||||
Exacerbations requiring OCS burst | 0.1 | 0.13 | 0.08 | [14] |
Exacerbations requiring ED visit | 0.15 | 0.19 | 0.11 | |
Exacerbations requiring hospitalization | 0.2 | 0.25 | 0.15 | |
Tiotropium effect | ||||
Relative risk on exacerbation rate | 0.72 | 0.83 | 0.62 | [12] |
Exacerbations | ||||
Exacerbation anua rate | 1.1 | 4 | 1 | |
# Hospitalization annual | 2.6 | 5 | 1 | |
Adherence of tiotropium | 61% | 76% | 57% | [18] |
Annual discount rate | 5.00% | 6% | 0% |